Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thcv + cbd
- Development stage
- Phase 2
- Lead developer
- InMed Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Sublingual, Topical, Inhalation, Transdermal
01
Overview
THCV + CBD is a combination of two phytocannabinoids derived from the cannabis plant—tetrahydrocannabivarin (THCV) and cannabidiol (CBD). THCV is a minor cannabinoid found primarily in certain sativa strains, noted for its potential to reduce appetite, support weight loss, improve metabolic health, and reduce anxiety. Unlike THC, THCV does not typically cause psychoactive effects unless consumed in high doses. It may also have neuroprotective properties and has been studied for possible benefits in type 2 diabetes and Parkinson’s disease[5][6]. CBD is a non-psychoactive cannabinoid widely researched for its anticonvulsant properties (notably as the active ingredient in Epidiolex), as well as potential roles in treating anxiety, pain, movement disorders such as Parkinson’s disease, and other neurological conditions[1][7][9]. Both cannabinoids act on the endocannabinoid system but with different affinities and mechanisms; THCV can act as an antagonist or partial agonist at cannabinoid receptors depending on dose/concentration while CBD acts mainly through indirect modulation of these receptors. The combination product "THCV/CBD" is not an FDA-approved pharmaceutical but may be available via medical cannabis programs or dietary supplement markets where permitted by law.
- Other names
- THCV/CBD
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on thcv + cbd.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thcv + cbd.